ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Treatment Outcomes of FSGS Recurrence

J. Mansur,1 D. Chang,2 G. Medeiros,1 M. Cristelli,1 L. Viana,1 S. Stopa,1 C. Felipe,1 G. Kirsztajn,1 H. Tedesco-Silva.1

1Hospital do Rim, Universidade Federal de Sao Paulo, Sao Paulo, Brazil
2Hospital Nacional Cayetano Heredia, Universidad Peruana Cayetano Heredia, Lima, Peru.

Meeting: 2018 American Transplant Congress

Abstract number: D111

Keywords: Kidney transplantation, Nephrotic syndrome, Plasmapheresis, Proteinuria

Session Information

Date: Tuesday, June 5, 2018

Session Name: Poster Session D: Kidney Complications: Late Graft Failure

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Hall 4EF

Related Abstracts
  • Analysis of FSGS (Focal Segmental Glomerulosclerosis) Recurrence After Renal Transplantation.
  • Recurrence of FSGS Post Kidney Transplantation: Salvage Therapy with ACTHAR® Gel.

Background: Recurrence of FSGS (focal segmental glomerulosclerosis) after kidney transplant occurs in 30% of adults and up to 80% of children and has impact on allograft survival. Remission rates varies from 30 to 90% and reduced allograft survival is observed. Despite this, there is no established treatment. We aim to evaluate the response to the multitargeted scheme for FSGS recurrence. Methods: Between january 2016 and may 2017, 13 patients were enrolled to received high dose prednisone, PE and cyclosporine for FSGS recurrence. Inclusion criteria were nephrotic range proteinuria without evidence of rejection, glomerulitis or allograft glomerulopathy on biopsy in a kidney transplant recipient (KTR) with FSGS as native kidney disease or undetermined etiology besides suggestive history of nephrotic syndrome. Results: Study population consisted young, mixed, male and non-obese adults with a median time on dialysis of 36 months who were receiving the first or second transplant primarily from deceased donors. 30% of them had biopsy proven FSGS and 70% had undetermined etiology. Median age for chronic kidney disease diagnosis was 39 years (3-60) with an interval of 59 months (0-252) to initiate dialysis. The majority of patients (92%) received thymoglobulin for induction therapy and tacrolimus, prednisone and azathioprine or mycophenolate as maintenance immunosuppression. Seventy percent of patients had early FSGS recurrence (< 6 months), with a median proteinuria of 4g/g, serum creatinine of 4,4 mg/dl and serum albumin of 3,2 g/dL. 50% of patients had confirmed FSGS on allograft biopsy. Median time to start treatment was 5 days (0-34) and all of them received 14 days of IV cyclosporine, 1 mg/kg oral prednisone and PE three times a week. Treatment was discontinued in 9 (69,2%) patients in a median time of 34 days (5-448) due to CMV infection. After discontinuation, 5 (38,4%) patients lost their grafts in a median time of 10 months (3,2-50). Complete and partial remission were observed in 2 (15,4%) and 4 (30,7%) patients. Two patients remain with nephrotic range proteinuria and stable GFR, one of them is in PE due to congestive symptoms. Conclusion: Current strategies used to treat FSGS recurrence are still not efficient with high rates of infection and graft loss and this continues to be a major problem after kidney transplantation.

CITATION INFORMATION: Mansur J., Chang D., Medeiros G., Cristelli M., Viana L., Stopa S., Felipe C., Kirsztajn G., Tedesco-Silva H. Treatment Outcomes of FSGS Recurrence Am J Transplant. 2017;17 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Mansur J, Chang D, Medeiros G, Cristelli M, Viana L, Stopa S, Felipe C, Kirsztajn G, Tedesco-Silva H. Treatment Outcomes of FSGS Recurrence [abstract]. https://atcmeetingabstracts.com/abstract/treatment-outcomes-of-fsgs-recurrence/. Accessed March 8, 2021.

« Back to 2018 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.